Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA53153
Max Phase: Preclinical
Molecular Formula: C18H22N4O6S
Molecular Weight: 422.46
Molecule Type: Small molecule
Associated Items:
ID: ALA53153
Max Phase: Preclinical
Molecular Formula: C18H22N4O6S
Molecular Weight: 422.46
Molecule Type: Small molecule
Associated Items:
Synonyms (1): sulfamidas3
Synonyms from Alternative Forms(1):
Canonical SMILES: CCCN(CCC)c1c([N+](=O)[O-])cc(S(=O)(=O)Nc2ccccc2)cc1[N+](=O)[O-]
Standard InChI: InChI=1S/C18H22N4O6S/c1-3-10-20(11-4-2)18-16(21(23)24)12-15(13-17(18)22(25)26)29(27,28)19-14-8-6-5-7-9-14/h5-9,12-13,19H,3-4,10-11H2,1-2H3
Standard InChI Key: RMNVGONASFTVGC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 422.46 | Molecular Weight (Monoisotopic): 422.1260 | AlogP: 3.93 | #Rotatable Bonds: 10 |
Polar Surface Area: 135.69 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.53 | CX Basic pKa: | CX LogP: 4.21 | CX LogD: 4.00 |
Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.45 | Np Likeness Score: -1.43 |
1. Bhattacharya G, Herman J, Delfín D, Salem MM, Barszcz T, Mollet M, Riccio G, Brun R, Werbovetz KA.. (2004) Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania., 47 (7): [PMID:15027874] [10.1021/jm0304461] |
2. Bhattacharya G, Salem MM, Werbovetz KA.. (2002) Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin., 12 (17): [PMID:12161141] [10.1016/s0960-894x(02)00465-1] |
3. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
4. Endeshaw MM, Li C, de Leon J, Yao N, Latibeaudiere K, Premalatha K, Morrissette N, Werbovetz KA.. (2010) Synthesis and evaluation of oryzalin analogs against Toxoplasma gondii., 20 (17): [PMID:20675138] [10.1016/j.bmcl.2010.07.003] |
5. Ma C, Tran J, Gu F, Ochoa R, Li C, Sept D, Werbovetz K, Morrissette N.. (2010) Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin., 54 (4): [PMID:20145086] [10.1128/aac.01150-09] |
6. Goodarzi M, da Cunha EF, Freitas MP, Ramalho TC.. (2010) QSAR and docking studies of novel antileishmanial diaryl sulfides and sulfonamides., 45 (11): [PMID:20728249] [10.1016/j.ejmech.2010.07.060] |
Source(1):